Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)

European Journal of Cancer

Volumn 50, Issue 17, 2014, Pages 2983-2993

  Bonnetain, Franck ^a   Bonsing, Bert ^b   Conroy, Thierry ^c   Dousseau, Adelaide ^d   Glimelius, Bengt ^e   Haustermans, Karin ^f   Lacaine, François ^g   Van Laethem, Jean Luc ^h   Aparicio, Thomas ⁱ   Aust, Daniela ^j   Bassi, Claudio ^k   Berger, Virginie ^l   Chamorey, Emmanuel ^m   Chibaudel, Benoist ⁿ   Dahan, Laeticia ^o   De Gramont, Aimery ⁿ   Delpero, Jean Robert ^p   Dervenis, Christos ^q   Ducreux, Michel ^r   Gal, Jocelyn ^m   Gerber, Erich ^s   Ghaneh, Paula ^t   Hammel, Pascal ^u   Hendlisz, Alain ^v   Jooste, Valérie ^w   Labianca, Roberto ^x   Latouche, Aurelien ^y   Lutz, Manfred ^z   Macarulla, Teresa ^aa   Malka, David ^r   Mauer, Muriel ^ab   Mitry, Emmanuel ^ac   Neoptolemos, John ^ad   Pessaux, Patrick ^ae   Sauvanet, Alain ^u   Tabernero, Josep ^aa   Taieb, Julien ^af   Van Tienhoven, Geertjan ^ag   Gourgou Bourgade, Sophie ^ah   Bellera, Carine ^ai   Mathoulin Pélissier, Simone ^ai   Collette, Laurence ^ab   more..

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Institute Cancer de Lorraine Alexis Vautrin   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e UPPSALA UNIVERSITY   (Sweden)

^f Department of Radiation Oncology ^*  (Belgium)

^g HÔPITAL TENON   (France)

^h ERASME HOSPITAL   (Belgium)

ⁱ AVICENNE HOSPITAL   (France)

^j UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^k Surgical and Gastroenterological Department Endocrine and Pancreatic Unit Hospital of 'Gbrossi'   (Italy)

^l UMR INSERM U892 CNRS 6299   (France)

^m CENTRE ANTOINE LACASSAGNE   (France)

ⁿ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^o TIMONE HOSPITAL   (France)

^p INSTITUT PAOLI CALMETTES   (France)

^q AGIA OLGA HOSPITAL   (Greece)

^r INSTITUT GUSTAVE ROUSSY   (France)

^s Kaiser Franz Josef Spital   (Austria)

^t ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^u BEAUJON HOSPITAL   (France)

^v JULES BORDET INSTITUTE   (Belgium)

^w Institut Médical de Génétique et d Immunologie   (France)

^x OSPEDALI RIUNITI   (Italy)

^y CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^z Department of Pathology   (Germany)

^aa HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^ab EORTC DATA CENTER   (Belgium)

^ac INSTITUT CURIE   (France)

^ad UNIVERSITY OF LIVERPOOL   (United Kingdom)

^ae Department of Digestive Surgery Universitu Hospital Strasbourg   (France)

^af HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^ag ACADEMIC MEDICAL CENTER   (Netherlands)

^ah CENTRE VAL D AURELLE   (France)

^ai INSTITUT BERGONIÉ   (France)

more..

Author keywords

Clinical trials; Consensus; Guidelines; Keywords Pancreatic cancer; Methodology; Time to event end point

Indexed keywords

CANCER GROWTH; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CONSENSUS DEVELOPMENT; DISEASE FREE SURVIVAL; FAILURE FREE SURVIVAL; FOLLOW UP; HUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SENSITIVITY ANALYSIS; TIME TO TREATMENT; BIOASSAY; CONSENSUS; DELPHI STUDY; MORTALITY; PANCREATIC NEOPLASMS;

CONSENSUS; DELPHI TECHNIQUE; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84925237877     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.07.011     Document Type: Review

References (19)

1. S. Mathoulin-Pelissier, S. Gourgou-Bourgade, and F. Bonnetain Survival end point reporting in randomised cancer clinical trials: a review of major journals J Clin Oncol 26 2008 3721 3726
2. Guidance for industry clinical trial end-points for the approval of cancer drugs and biologics, Food and Drugs Administration, Department of Health and Human Services, 2007.
3. T.R. Fleming, M.D. Rothmann, and H.L. Lu Issues in using progression-free survival when evaluating oncology products J Clin Oncol 27 2009 2874 2880
4. R.A. Nout, W.E. Fiets, and H. Struikmans The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer Breast Cancer Res Treat 109 2008 567 572
5. C.J. Punt, M. Buyse, and C.H. Kohne End-points in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials J Natl Cancer Inst 99 2007 998 1003
6. J.M. Llovet, A.M. Di Bisceglie, and J. Bruix Design and end-points of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
7. C.A. Hudis, W.E. Barlow, and J.P. Costantino Proposal for standardised definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system J Clin Oncol 25 2007 2127 2132
8. C.A.P.M. Bellera, S. Gourgou, L. Collette, A. Doussau, A. Kramar, and S. Dabakuyo Protocol of the DATECAN study: formal consensus method for the development of guidelines for standardised time-to-event end-points' definitions in cancer clinical trials Eur J Cancer 49 2013 769 781
9. K. Fitch, S. Bernstein, and M. Aguilar The RAND/UCLA appropriateness method user's manual 2001 Santa Monica RAND
10. Bases méthodologiques pour l'élaboration de recommandations professionnelles par consensus formalisé, Haute Autorité en Santé, 2006.
11. MeSH - National library of medicine's controlled vocabulary thesaurus http://www.nlm.nih.gov/pubs/factsheets/mesh.html.
12. J. Jones, and D. Hunter Consensus methods for medical and health services research BMJ 311 1995 376 380
13. Linstone AH, Turoff M: The Delphi Method: techniques and applications. (ed Addison-Wesley Pub. Co.), Linstone & Turoff Editors, 1975.
14. Murphy MK, Black NA, Lamping DL, et al.: Consensus development methods, and their use in clinical guideline development. Health Technol Assess 2:i-iv, 1-88, 1998.
15. J.P. Neoptolemos, M.J. Moore, and T.F. Cox Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine versus observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomised trial JAMA 308 2012 147 156
16. P.J. Loehrer Sr.; Y. Feng, and H. Cardenes Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial J Clin Oncol 29 2011 4105 4112
17. H. Oettle, S. Post, and P. Neuhaus Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cancer: a randomised controlled trial JAMA 297 2007 267 277
18. J.A. Hattangadi, T.S. Hong, and B.Y. Yeap Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma Cancer 115 2009 3640 3650
19. H. Birgisson, U. Wallin, and L. Holmberg Survival end-points in colorectal cancer and the effect of second primary other cancer on disease free survival BMC Cancer 11 2011 438